Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Rhea-AI Summary

Scienture Holdings (NASDAQ:SCNX) has successfully regained compliance with Nasdaq's minimum bid price requirement by maintaining a closing bid price of $1.00 or higher for ten consecutive business days. This resolves the non-compliance notice received on May 19, 2025, which had given the company until November 17, 2025, to meet the listing requirement.

The company's leadership expressed satisfaction with this development, particularly as they prepare for the upcoming launch of their first FDA-approved product, Arbli™. The management team emphasized their continued focus on creating stockholder value and bringing novel therapies to market.

Positive

• None.

Negative

• Previously faced delisting risk due to minimum bid price non-compliance

Insights

Capital Markets Specialist

Scienture regains Nasdaq compliance by meeting minimum bid price requirements, averting potential delisting risks ahead of new product launch.

Scienture Holdings' announcement of regaining Nasdaq compliance represents a critical development for the pharmaceutical holding company. After falling below the $1.00 minimum bid price requirement in May 2025, the company has successfully maintained its share price above this threshold for the required ten consecutive trading days, well ahead of the November 17, 2025 deadline.

The significance of maintaining Nasdaq listing cannot be overstated. Delisting would have triggered numerous adverse consequences, including reduced liquidity, limited access to institutional investors, potential loan covenant violations, and diminished ability to raise capital. These factors would have been particularly damaging given the company's upcoming product launch plans.

The compliance recovery indicates potential improved market sentiment toward Scienture, especially noteworthy considering the company's upcoming launch of Arbli™, its first FDA-approved product. This product launch represents a pivotal milestone in the company's development trajectory, transitioning from development to commercialization.

While the press release doesn't provide specific details on how the company achieved compliance (whether through organic share price appreciation or corporate actions like a reverse stock split), the early resolution of this regulatory challenge allows management to redirect focus to operational priorities rather than navigating delisting procedures. For shareholders, this development removes a significant near-term risk factor that could have substantially impacted investment value.

Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has received a notification letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of the Company’s common stock has been at $1.00 per share or greater for the previous ten consecutive business days.

As previously disclosed, on May 19, 2025, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Company’s common stock, for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing as set forth in Nasdaq Listing Rule 5550(a)(2). At that time, the Company was provided a compliance period of 180 calendar days from the date of the letter, or until November 17, 2025, to regain compliance.

“We are pleased with the efforts of our team to regain compliance with Nasdaq Listing Rule 5550(a)(2) and ensure that our common stock will continue to be listed on Nasdaq,” said Shankar Hariharan, Co-Chief Executive Officer and Executive Chairman of the Company. “We continue to focus on and are excited about creating value for our stockholders, especially with the upcoming launch of our first FDA-approved product, Arbli^™.”

“Regaining compliance with Nasdaq listing requirements allows us to place our full attention on our upcoming product launches and working toward our goal of improving patient outcomes,” commented Narasimhan Mani, Co-Chief Executive Officer and President. “I am excited about our future and look forward to continuing to bring to market novel therapies that provide value for patients, the healthcare system, and our stockholders.”

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiaries, including Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information, please visit www.scientureholdings.com and www.scienture.com.

Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “seek,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

For more information, please contact:
IR@Scienture.com

FAQ

When did Scienture Holdings (SCNX) regain Nasdaq compliance?

Scienture Holdings regained Nasdaq compliance in July 2025 after maintaining a closing bid price above $1.00 for ten consecutive business days.

What was the deadline for Scienture Holdings (SCNX) to regain Nasdaq compliance?

Scienture Holdings had until November 17, 2025 to regain compliance with Nasdaq's minimum bid price requirement.

What is Scienture Holdings' (SCNX) first FDA-approved product?

Scienture Holdings' first FDA-approved product is Arbli™, which is scheduled for upcoming launch.

What was the minimum bid price requirement for Scienture Holdings (SCNX) to maintain Nasdaq listing?

Scienture Holdings needed to maintain a minimum bid price of $1.00 per share for at least ten consecutive business days to comply with Nasdaq Listing Rule 5550(a)(2).

Who are the current leaders of Scienture Holdings (SCNX)?

Scienture Holdings is led by Shankar Hariharan as Co-Chief Executive Officer and Executive Chairman, and Narasimhan Mani as Co-Chief Executive Officer and President.